RxDoctor Payments Data

Michael Roberts, MD

Ophthalmology · Glendale, CANPI 1396738530

Payments from drug & device makers

$2,702in general payments, 2019–2025

Across 28 payments — averaging $96.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • AbbVie$187
  • Aerie Pharmaceuticals, Inc.$114
  • Sight Sciences, Inc.$112
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$69
  • Glaukos Corporation$63
  • plus $96 from 5 others

What the payments were for

  • Speaking & faculty fees$1,92571%
  • Food & beverage$77729%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,702 in reported general payments places this provider in the 60th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$114,849
Medicare patients
268
Services billed
942

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RocklatanNetarsudil Mesylat/Latanoprost107$39,927
RestasisCyclosporine32$32,195
IlevroNepafenac71$25,791
LumiganBimatoprost52$22,631
RhopressaNetarsudil Mesylate27$10,010
Difluprednate99$8,358
Travoprost41$8,338
Cyclosporine11$8,115
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol41$5,856
Latanoprost651$5,276
CombiganBrimonidine Tartrate/Timolol15$4,743
Brimonidine Tartrate54$4,406
MoxifloxacinMoxifloxacin Hcl150$3,385
SimbrinzaBrinzolamide/Brimonidine Tart11$3,049
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat153$2,167

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$187$59,56899 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$114$49,936134 claims
AlconSimbrinza$2,062$3,04911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Glendale

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →